Floatz logo

Carboplatin

Uterine Cervical Neoplasms

Eli Lilly and CompanySmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Uterine Cervical Neoplasms cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
GV20 Therapeutics
Phase 3BB
FULVESTRANT
Atavistik Bio, Inc
Phase 2B
LENVATINIB
Merck Sharp & Dohme LLC
Phase 2B
Docetaxel
Merck Sharp & Dohme LLC
Phase 2B

View all 29 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →